Compare Amylx Pharmaceuticals Inc (AMLX) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Charles Schwab Corporation Common Stock — how do they compare? Amylx Pharmaceuticals Inc trades at $17.65 (market cap $1.98B), while Charles Schwab Corporation Common Stock trades at $103.71 (market cap $179.34B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 90.6× Amylx Pharmaceuticals Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.24% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | SCHW | |
|---|---|---|
Market Cap | $1.98B | $179.34B |
Sector | Health | Financials |
52-Week High | $18.70 | $107.21 |
52-Week Low | $7.64 | $85.35 |
Enterprise Value | $1.70B | — |
Dividend Yield | — | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Charles Schwab (SCHW) trades at $103.12, up 1.19% today, near its pivot point of $102 with bullish technical momentum. The stock shows strong fundamentals with a 37.99% net income margin and 21.79% ROE, supported by three consecutive quarterly earnings beats. Recent news highlights a Zacks upgrade to Strong Buy and a four-year high in the Schwab Trading Activity Index, reflecting robust retail engagement.
Outlook remains positive with a consensus price target of $122.71 implying 19% upside, though overbought RSI signals near-term caution. Risks include interest rate sensitivity and competitive pressures, but institutional bullishness and expanding prediction market initiatives offer growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
